Evidence map›Paper›PMID 40613708›Full record

ArticleNucleic acids research2025

The inflammasome sensor NLRP3 interacts with REV7 to maintain genome integrity through homologous recombination.

Delphine Burlet, Md Muntaz Khan, Sabine Hacot, Hannes Buthmann, Léa Bardoulet, Anne-Laure Huber, Julie Gorry, Bastian Föhr, Bernard S Lopez, Yohann Couté and 4 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Delphine BurletINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Md Muntaz KhanINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Sabine HacotINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Hannes ButhmannInstitute of Structural Biology, University of Bonn, D-53127 Bonn, Germany.
Léa BardouletINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Anne-Laure HuberINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Julie GorryINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Bastian FöhrBiochemistry of Signal Dynamics, Max Planck Institute for Multidisciplinary Sciences D-37077, Göttingen, Germany.
Bernard S LopezUniversité de Paris, Inserm U1016, CNRS UMR 8104, Institut Cochin, F-75014 Paris, France.ORCID 0000-0001-5088-0155
Yohann CoutéUniversité Grenoble Alpes, INSERM, CEA, UA13 BGE, CNRS, CEA, FR2048, F-38000 Grenoble, France.ORCID 0000-0003-3896-6196
Alex C FaesenBiochemistry of Signal Dynamics, Max Planck Institute for Multidisciplinary Sciences D-37077, Göttingen, Germany.
Matthias GeyerInstitute of Structural Biology, University of Bonn, D-53127 Bonn, Germany.
Agnès TissierINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.
Virginie PetrilliINSERM U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France.ORCID 0000-0001-8502-6979

Funding

Agence Nationale de la Recherche under projects Proteomics French Infrastructure ANR-10-INBS-08Chemistry Biology Health Graduate School of University Grenoble Alpes ANR-17-EURE-0003European Research Council NalpACTFondation de Recherche Médicale DEQ20170336744Fondation de Recherche Médicale PMT202407019320German Research FoundationGermany's Excellence Strategy DFGGermany's Excellence Strategy EXC2151-390873048Germany's Excellence Strategy GE 976/16-1Institut Convergence PLAsCAN ANR-17-coNV-0002Institut National du Cancer PLBIO24-196-2024-158Ligue contre le cancerLigue contre le cancer comité de l'Ain, Cantal, Loire, Saône-et-Loire, and DrômeMarie Skłodowska-Curie 751216Max Planck SocietyMSDAvenir Erican
6 · The paper itself

Abstract

DNA double-strand break (DSB) is a highly toxic lesion that can generate genome instability, a major source of tumorigenesis. DSBs are mainly repaired by non-homologous end joining (NHEJ) or homologous recombination (HR). The selection of the DSB repair pathway primarily depends on the DNA resection of the DSB ends. Indeed, HR is initiated by resection at the DSB, generating 3' single-stranded overhang. The shieldin complex prevents resection fostering DSB repair toward NHEJ. Here, we reveal that the inflammasome sensor NLRP3 facilitates DNA end resection to promote the HR pathway in an inflammasome-independent manner. Strikingly, NLRP3 silencing decreases HR efficiency, as evidenced by RAD51 foci and functional HR assays. Mechanistically, we describe that NLRP3 interacts with REV7, a subunit of the shieldin complex, and its depletion increases REV7 recruitment to IR-induced DSBs. Similar to cancer cells harboring HR-mutated genes, we find that NLRP3-deficient cells are sensitive to Poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) and exhibit an epistatic relationship with BRCA1 deficiency. Remarkably, loss of REV7 in NLRP3-depleted cells induces PARPi resistance by restoring HR. This study unravels the crucial role of the innate immune receptor NLRP3 in regulating the selection of DSB repair pathways to maintain genome integrity.

Indexed as

Cell Cycle ProteinsDNA-Binding ProteinsGenomic InstabilityHomologous RecombinationInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinDNA Breaks, Double-StrandedDNA End-Joining RepairHEK293 CellsHumansMad2 ProteinsPoly(ADP-ribose) Polymerase InhibitorsCell Cycle ProteinsDNA-Binding ProteinsInflammasomesMAD2L2 protein, humanMad2 ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID40613708
PMCPMC12231572

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.